Kenneth Pennington, MD

Articles by Kenneth Pennington, MD

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

ByKathy D. Miller, MD,Judy Sisk, RN,Rafat Ansari, MD,Gary Gize, MD,Sreenivasa Nattam, MD,Kenneth Pennington, MD,George W. Sledge, Jr, MD

February 1st 2001

A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing

Latest Updated Articles

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Published: February 1st 2001 | Updated:

Kenneth Pennington, MD

Articles by Kenneth Pennington, MD

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment